Hilyatuz Zahroh

Hilyatuz Zahroh

Auto-generated profile, based on publicly available information

Hilyatuz Zahroh

Department of Pharmacology, Faculty of Medicine & Dentistry, College of Health Sciences University of Alberta Edmonton Alberta Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
EIEsra Büşra Işık
Esra Büşra Işık
MBMichelle D. Brazas
Michelle D. Brazas
RSRussell Schwartz
Russell Schwartz
BGBruno Gaeta
Bruno Gaeta
PPPatricia M. Palagi
Patricia M. Palagi
MKMohammad Asif Khan
Mohammad Asif Khan

1 July 2018 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
SSSupharat Suvichapanich
Supharat Suvichapanich
KFKoya Fukunaga
Koya Fukunaga
HZHilyatuz Zahroh
Hilyatuz Zahroh
TMTaisei Mushiroda
Taisei Mushiroda
SMSurakameth Mahasirimongkol
Surakameth Mahasirimongkol
KTKatsushi Tokunaga
Katsushi Tokunaga
NAT2 slow acetylator is a confirmed risk of anti-tuberculosis drug-induced liver injury (ATDILI). However, NAT2 ultra-slow acetylators, a new refinement among NAT2 slow acetylators, have been recently proposed. The patients with NAT2 genotypes of *6A/*6A, *6A/*7B and *7B/*7B are referred to in this group. We aim to prove an association of the NAT2 ultra-slow acetylators with the risk of ATDILI. Systematic review and meta-analysis were performed based on each NAT2 genotype and risk of ATDILI cases and also new classification of the ultra-slow acetylators up to 31 October 2016. Meta-analysis of 18 studies with 822 ATDILI cases and 4630 controls was carried out in the RevMan software, version 5.3 with fixed-effect (low heterogeneity) and random effect (moderate to high heterogeneity) methods. The strong associations between each NAT2 slow acetylator genotypes and ATDILI were confirmed in meta-analysis except for NAT2*5B/*5B [odds ratio (OR): 1.69; 95% confidence interval (CI): 0.96-2.95; P=0.0679]. The NAT2 ultra-slow acetylators contribute to higher risk of ATDILI (OR: 3.60; 95% CI: 2.30-5.63; P=1.76E-08) than all NAT2 slow acetylators (OR: 2.80; 95% CI: 2.20-3.57; P=5.73E-18) as well as fast acetylators. Additional in-vitro study using isoniazid as a substrate supports the existence of ultra-slow acetylator alleles (NAT2*6A and NAT2*7B). This is the first meta-analysis of NAT2 and the risk of ATDILI at the genotypic level. The result demonstrated that NAT2 ultra-slow acetylator genotypes will have the most effect on the increased risk of ATDILI.

1 January 2016 in Drug Target Insights
Verified
Journal Article
Open access
HZHilyatuz Zahroh
Hilyatuz Zahroh
AMAhmad Ma'RUp
Ahmad Ma'RUp
UTUsman Sumo Friend Tambunan
Usman Sumo Friend Tambunan
APAril Aditya Parikesit
Aril Aditya Parikesit
Meningitis infection is one of the major threats during Hajj season in Mecca. Meningitis vaccines are available, but their uses are limited in some countries du...

1 January 2015 in Drug Target Insights
Verified
Journal Article
Open access
UTUsman Sumo Friend Tambunan
Usman Sumo Friend Tambunan
HZHilyatuz Zahroh
Hilyatuz Zahroh
Arli Aditya ParikesitArli Aditya Parikesit
Arli Aditya Parikesit
SISyarifuddin Idrus
Syarifuddin Idrus
DKDjati Kerami
Djati Kerami
Dengue is an infectious disease caused by dengue virus (DENV) and transmitted between human hosts by mosquitoes. Recently, Indonesia was listed as a country wit...

11 July 2025 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
AIAsmaa Ibrahim
Asmaa Ibrahim
RAReem Alenany
Reem Alenany
LBLoulia Bader
Loulia Bader
FNFatima Nazar
Fatima Nazar
SASara Abul-Ola
Sara Abul-Ola
FMFatima Mraiche
Fatima Mraiche
Pharmacogenomics (PGx) is a crucial part of precision medicine; however, its integration into clinical practice has been slow, primarily due to knowledge gaps regarding pharmacogenomics among healthcare professionals (HCPs). Pharmacogenomics education is considered the most influential barrier to the successful implementation of PGx. In the Middle East and North Africa (MENA) region, several studies have highlighted the lack of PGx education among students and HCPs. This scoping review aims to provide an overview of the existing literature on how PGx is delivered in the curricula and its impact on knowledge acquisition among students and HCPs in the MENA region. A database search of PubMed, Embase, and CINAHL was conducted up to June 2023. Outcomes included PGx education availability, curriculum placement, mode of delivery, and knowledge level. Seven cross‐sectional studies were identified (2014–2023), with 57% from the Gulf region. PGx education is mostly taught to undergraduates (71%) through didactic lectures (100%), with only a few studies reporting a standalone course (29%). Participants demonstrated low (43%) to moderate (43%) knowledge levels, assessed using objective scales or subjective self‐assessment after completion of the course. Reported barriers to implementing PGx education included knowledge gaps, economic constraints, and system sustainability. PGx education in the MENA region is delivered mainly as an integrated course in professional programs including pharmacy and medicine, and the overall knowledge level was low to moderate. Future research could focus on providing more detailed reporting of the PGx educational landscape, developing standardized assessment tools, and evaluating actual knowledge acquisition among different professions.

30 September 2016 in International Journal of Biomass and Renewables
Verified
Journal Article
Open access
YSYusraini Dian Inayati Siregar
Yusraini Dian Inayati Siregar
RKRyo Kawakami
Ryo Kawakami
SIShota Ito
Shota Ito
YIYuuta Inoue
Yuuta Inoue
THTetsuya Hirota
Tetsuya Hirota
ASAgus Salim
Agus Salim